Targeted genome editing by artificial nucleases has brought the goal of site-specific transgene integration and gene correction within the reach of gene therapy. However, its application to long-term repopulating haematopoietic stem cells (HSCs) has remained elusive. Here we show that poor permissiveness to gene transfer and limited proficiency of the homologydirected DNA repair pathway constrain gene targeting in human HSCs. By tailoring delivery platforms and culture conditions we overcame these barriers and provide stringent evidence of targeted integration in human HSCs by long-term multilineage repopulation of transplanted mice. We demonstrate the therapeutic potential of our strategy by targeting a corrective complementary DNA into the IL2RG gene of HSCs from healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1). Gene-edited HSCs sustained normal haematopoiesis and gave rise to functional lymphoid cells that possess a selective growth advantage over those carrying disruptive IL2RG mutations. These results open up new avenues for treating SCID-X1 and other diseases.
Targeted genome editing by artificial nucleases has brought the goal of site-specific transgene integration and gene correction within the reach of gene therapy. However, its application to long-term repopulating haematopoietic stem cells (HSCs) has remained elusive. Here we show that poor permissiveness to gene transfer and limited proficiency of the homologydirected DNA repair pathway constrain gene targeting in human HSCs. By tailoring delivery platforms and culture conditions we overcame these barriers and provide stringent evidence of targeted integration in human HSCs by long-term multilineage repopulation of transplanted mice. We demonstrate the therapeutic potential of our strategy by targeting a corrective complementary DNA into the IL2RG gene of HSCs from healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1). Gene-edited HSCs sustained normal haematopoiesis and gave rise to functional lymphoid cells that possess a selective growth advantage over those carrying disruptive IL2RG mutations. These results open up new avenues for treating SCID-X1 and other diseases.
Haematopoietic stem cell (HSC)-based gene therapy has provided therapeutic benefit in primary immunodeficiencies 1, 2 , thalassaemia 3 and leukodystrophies 4, 5 . Whereas more advanced vectors, such as lentiviral vectors 6 , have shown improved safety and efficacy, the risk of insertional mutagenesis 7, 8 and unregulated transgene expression 9,10 remains a concern when using semi-randomly integrating vectors. These adverse effects may trigger oncogenesis, toxicity or elimination of the gene-modified cells.
Artificial endonucleases, such as zinc finger nucleases (ZFNs) 11 , transcription activator-like effector nucleases (TALENs) 12 , and RNA-guided nucleases (CRISPR/Cas) 13 , brought the possibility of gene targeting within the reach of gene therapy 14, 15 . These nucleases are used to efficiently and specifically target a DNA double-strand break (DSB) to a pre-selected genomic site 13, 16, 17 . According to the repair process that seals the break 18 , the outcome can be disruption, reconstitution or editing of the original sequence. If the DSB is sealed by the error-prone non-homologous endjoining (NHEJ) pathway, insertions and deletions (indels) are common [19] [20] [21] . If the DSB is sealed by the high-fidelity homology directed repair (HDR) pathway, which acts preferentially during the S/G2 phase, the targeted sequence can be edited by providing an exogenous DNA template flanked by homologous sequences to the nuclease target site. Targeted editing allows for the integration of an expression cassette into a safe genomic harbour 22, 23 , or correcting disease-causing mutations by inserting a functional copy of the affected gene downstream of its own promoter 14, 24 . Gene correction, as opposed to gene replacement, may not only restore the function but also the physiological expression of the gene, a longsought goal of gene therapy.
Whereas gene disruption by ZFNs has been shown in human haematopoietic stem/progenitor cells (HSPCs) assayed by repopulation of SCID mice 20 , targeted gene editing in these cells has not been reported.
Here we identify and overcome major constraints limiting gene targeting in HSPCs and provide proof-of-efficacy for this approach by functional reconstitution of the IL2RG gene, mutations of which are responsible for SCID-X1.
Site-specific integration in human HSPCs
We developed a protocol for delivery of ZFNs and donor DNA template into human umbilical cord blood CD34 1 cells by mRNA electroporation and integrase-defective lentiviral vector (IDLV), and targeted integration of a GFP cassette into the AAVS1 'safe harbour' 22 or a mutational hotspot of IL2RG (refs 14, 15) ( Fig. 1a, b and Extended Data Fig. 1 ). This protocol yielded on average 5% GFP 1 cells in liquid culture and colony-forming cell (CFC) assays and high percentages of indels in the respective ZFN target sites, although after a transient cell loss ( Fig. 1c and Extended Data Fig. 2a-e ). PCR analysis and Southern blot showed integration of the GFP cassette at the intended targets in .90% of the GFP 1 colonies (n 5 89) and in induced pluripotent stem cells obtained by reprogramming the GFP 1 sorted cells (Fig. 1d , e and Extended Data Fig. 2f , g). We then transplanted the CD34 1 cells treated for AAVS1 or IL2RG gene targeting into NOD-SCID-Il2rg 2/2 (NSG) mice and found human cell engraftment in all mice ( Fig. 2a ). In the first 8 weeks after transplant, 95% of the mice had circulating GFP 1 cells (mean 6.2 6 1.3%; Fig. 2b ), whereas only 42% of the mice maintained long-term GFP marking. End-point analyses performed on the peripheral blood, spleen and bone marrow showed that GFP 1 cells were present within all human haematopoietic lineages, including lymphoid and myeloid cells, and erythroid precursors (mean 2 6 0.8%; Fig. 2c ). Similar frequencies of GFP 1 cells were found among primitive and committed progenitors in the bone marrow (mean 2.2 6 0.9%; Fig. 2d ). PCR analyses confirmed targeted integration in human lymphoid, myeloid and CD34 1 cells from the spleen and bone marrow of representative mice ( Fig. 2e ). CFC assays on CD34 1 cells from bone marrow showed GFP 1 myeloid and erythroid colonies ( Fig. 2f ) with targeted integration ( Fig. 2e ). Analysis of bone marrow cells showed the occurrence of NHEJ-mediated indels in the ZFN target site in the majority of mice (64%; Fig. 2g ) at higher levels than observed for GFP marking, indicating that DNA DSB induction and repair by either HDR or NHEJ is compatible with haematopoietic repopulation. Overall, these data show that our gene targeting protocol achieves site-specific integration in human multipotent longterm NSG repopulating cells (SRCs), surrogate readouts of HSCs.
Low targeting efficiency in HSPCs
The in vivo studies revealed that only ,40% of mice had on average 2% human GFP 1 cells over the long term. These figures seem lower than expected from transplanting CD34 1 cells with ,5% targeting efficiency in vitro (Supplementary Information) and suggest that either SRCs are targeted less efficiently than the bulk CD34 1 cells, or the gene-targeted SRCs have a competitive disadvantage in vivo. We thus compared the percentages of GFP 1 cells among different subpopulations of cultured CD34 1 cells, prospectively identified by surface markers 25 as primitive (CD34 1 CD133 1 CD90 1 ), early (CD34 1 CD133 1 CD90 2 ) and committed (CD34 1 CD133 2 ) progenitors, and the differentiated cells (CD34 2 , Fig. 3a , left panel). We found a decreasing frequency of GFP 1 cells when moving from the differentiated cells up the progenitor hierarchy. In primitive cells the percentage of GFP 1 cells was 20-fold lower than that measured in differentiated cells. We thus investigated the potential rate-limiting steps for gene targeting in primitive cells (Extended Data Fig. 3a-d ). Transgene expression on mRNA electroporation was similar among the subpopulations or slightly lower for the primitive cells. The level of NHEJ induced at the ZFN target site was higher in the primitive cells and progressively lower in committed and differentiated cells. This difference, however, diminished with time in culture, potentially due to the loss of some treated primitive cells. Indeed, induction of apoptosis was higher in this subset. Taken together these data indicate that the primitive cells are more sensitive to our treatment and less permissive to HDR and/or donor template delivery.
Tailored conditions improve HSC gene targeting
Because cell-cycle progression is a requirement of HDR and activation of the primitive progenitors may require longer stimulation, we postponed the gene targeting procedure to the third day of culture ( Fig. 3b ). At this time, the cells are also likely to become more permissive to lentiviral vector transduction. Because increasing the length of time in culture promotes differentiation, we added the aryl hydrocarbon receptor antagonist (StemRegenin 1, SR1) 26 and/or 16,16-dimethyl-prostaglandin E2 (dmPGE2) 27, 28 to the culture to better preserve stem and early progenitor cells (Fig. 3c ). The delayed protocol significantly increased ($2-fold) the percentage of GFP 1 cells in primitive cells (Fig. 3a , right panels). SR1 slightly reduced the percentage of GFP 1 cells observed within each subpopulation but increased the yield of GFP 1 CFCs and early progenitors consistently with the increased proportion of immature cells in SR1-treated cultures (Fig. 3d , e and Extended Data Fig. 3e ). The addition of dmPGE2 increased the percentage of GFP 1 cells in all subpopulations when used alone and showed additive effects with SR1. Notably, both the delayed treatment and the addition of SR1 and dmPGE2 increased the fraction of mice showing long-term engraftment with GFP 1 cells, which reached 100% when used in combination ( Fig. 3f ). Human cell engraftment significantly increased after addition of SR1 to the culture ( Fig. 3g ) and was stable long-term (Extended Data Fig. 4a, b ). Consistent with the increased GFP marking observed in vitro in the primitive cells, the mean percentage of GFP 1 cells showing long-term engraftment in vivo increased with all types of delayed treatments (Fig. 3h ). GFP 1 cells contributed to multiple lineages and to the progenitor compartment in most mice (Extended Data Fig. 4c, d ). Molecular analyses on bone marrow cells showed evidence of targeted integration (Extended Data Fig. 4e ). Serial transplant of purified CD34 1 cells from the bone marrow of primary mice showed engraftment and differentiation of targeted GFP 1 cells in secondary recipients (Extended Data Fig. 4f, g) . 
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Overall, these data indicate that by tailoring experimental conditions we could improve the yield and frequency of targeted long-term SRCs.
Targeted gene editing of IL2RG in HSPCs
In the experiments described in Fig. 3g , h, the gene targeting construct was designed to insert a cDNA comprising exons 5-8 of IL2RG together with the GFP cassette into the IL2RG gene and used on CD34 1 cells from healthy male donors (Fig. 4a ). In this way, the cDNA is transcribed from the endogenous IL2RG promoter and spliced to its upstream exons, thus providing a platform for correcting all SCID-X1-causing mutations downstream of exon 4. To assess functional reconstitution of the targeted gene, we challenged the repopulated mice with a human tumour cell line (MDA-MB 231) engineered to express human interleukin (IL)-7, IL-15 and granulocyte-macrophage colony-stimulating factor (GM-CSF) ( Fig. 4b ). We previously reported that this challenge leads to improved reconstitution of functional human T and natural killer (NK) cells that eventually reject the tumour graft 29 . T and NK cells are strictly dependent on IL-2RG expression for survival and activity and are absent in SCID-X1. On tumour challenge, we observed a massive (mean 130 6 40-fold) expansion of the human T and NK lineages in the repopulated mice (Extended Data Fig. 5 ). GFP 1 T and NK cells expressed IL-2RG on the cell surface ( Fig. 4c ) and expanded similarly to their GFP-negative counterparts in all mice ( Fig. 4d ). All repopulated mice effectively rejected the allogeneic tumour, at variance with non-transplanted mice, underscoring the development of a functional human immune system ( Fig. 4e ). Whereas myeloid cells sorted from the mice showed high levels of NHEJ at the targeted IL2RG site, comparable to those observed in the CD34 1 cells pre-transplant, B cells showed very little NHEJ, and T and NK cells showed virtually no NHEJ (Fig. 4f ). These findings reflect the marked counter selection of lymphoid cells carrying a disrupted IL2RG, as it naturally occurs with inherited SCID-X1 alleles, and confirm the functionality of the reconstituted gene in the expanded GFP 1 cells. We then assessed the T-cell-receptor repertoire of lymphocytes from the engrafted mice and found substantial diversity with almost overlapping polyclonal pattern between the GFP 1 and GFP 2 sorted cell subsets ( Fig. 4g and Extended Data Fig. 6 ). The GFP 1 and GFP 2 T cells expanded ex vivo after polyclonal stimulation with the same kinetics in the presence of c-chain-dependent cytokines (IL-7 and IL-15), and proliferated to a similar extent in response to the allogeneic MDA-MB 231 cells (Fig. 4h , i and Extended Data Fig. 7a ). GFP 1 and GFP 2 T cells were similarly comprised of CD8 and CD4 cell subsets, with most cells showing effector phenotypes (Extended Data Fig. 7b , c). Consistently, both GFP 1 and GFP 2 cells robustly produced IFN-c and IL-2 after phorbol myristate acetate (PMA)-ionomycin stimulation or when co-cultured with the allogeneic tumour at different effector/target ratios (Extended Data Fig. 7d, e ). Molecular analyses demonstrated that nearly all GFP 1 cells contained targeted integration into IL2RG (Fig. 4j ). We then measured the phosphorylation of two downstream effectors in the signalling 
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cascade of c-chain-coupled receptors ( Fig. 4k and Extended Data Fig. 8 ).
The targeted T cells displayed similar kinetics and extent of phosphorylation of STAT5 and AKT as their GFP 2 counterparts after stimulation with increasing IL-15 and IL-2 doses. Overall, these data prove functional reconstitution of the edited IL2RG gene, which supported lymphopoiesis and mature T-cell function indistinguishably from the wild-type allele.
Specificity of IL2RG ZFNs on the HSC genome
We previously performed a genome-wide screening in K562 cells to identify potential off-target sites of the IL2RG ZFNs used in this study 16 and found a low rate of indels in up to 12 genomic loci bearing homology to the intended target site. We then determined whether these sites were also affected in the HSPCs treated here with ZFNs containing the same IL2RG DNA-binding domains but coupled to improved obligate heterodimeric FokI domains. We deep-sequenced the genomic regions encompassing the identified potential target sites on treated CD34 1 cells cultured in vitro and on human cells from the bone marrow of longterm engrafted NSG mice ( Table 1 and Extended Data Fig. 9 ). The intended IL2RG target site showed 45-61% indel rate in the in vitro cultured cells and 20-43% in the in vivo engrafted cells. However, we detected indels only in two in vitro samples (at 0.17-0.7%) for the top two previously identified off-target sites, whereas from the in vivo samples we found just one site with evidence of NHEJ (at 0.02%). Deep sequencing of all other putative off-target sites gave results not statistically different from the background error rate, which limits detection at 0.01% in our analysis (see Supplementary Information) . The elimination of detectable off-target activity at some previously identified sites is consistent with the adoption of obligate heterodimeric FokI variants in this study, which would detarget activity from sites requiring ZFN homodimers. This analysis demonstrates a high specificity for the ZFNs used, evidenced by the 100-fold ratio between activities at the intended target site versus the top identified off-target site. It is possible, however, that additional off-target sites exist, which have not been identified by our previous screening.
IL2RG gene correction in SCID-X1 HSPCs
We applied the optimized protocols developed for umbilical cord blood to CD34 1 cells from adult bone marrow and obtained an overall genetargeting efficiency of 6 6 0.5% (n 5 4 donors) and a high rate of indels induced at either the AAVS1 or IL2RG ZFN target sites ( Fig. 5a ). Targeting was less efficient in the more primitive populations, although reaching similar values as those observed for umbilical cord blood cells. Xenotransplantation proved the long-term multilineage repopulation capacity of the targeted cells, with all transplanted NSG mice bearing GFP 1 cells at frequencies comparable to those observed with umbilical cord d, Expansion of GFP 2 and GFP 1 T and NK cells after tumour challenge. e, Tumour weight 3 weeks after challenge, in mice transplanted (n 5 16) or not (n 5 3). ****P , 0.0001 (unpaired t-test). f, NHEJ in the IL2RG gene on CD34 1 cells cultured in vitro and on their progeny sorted from the transplanted mice. g, TCR complexity score calculated on GFP 1 or GFP 2 T cells from transplanted mice. Human peripheral blood mononuclear cells (PBMCs) were used as positive control. ****P , 0.0001 (one-way ANOVA). h, Ex vivo growth of GFP 1 and GFP 2 T cells from the spleen of transplanted mice on stimulation (n 5 4). i, Division index of GFP 1 or GFP 2 T cells 7 days after PHA stimulation or co-culture with tumour cells at the indicated effectorto-target (E/T) ratios. P 5 NS (not significant) (unpaired t-test). T cells from healthy donor (HD) were used as controls. 
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blood cells ( Fig. 5b ). On the basis of these results, we then tested our gene correction strategy on bone marrow CD34 1 cells from a symptomatic four-month-old SCID-X1 patient bearing a missense mutation in IL2RG exon 7 (c.865C.T; R289X). As expected for this mutation, blood sampling or bone marrow harvest from the patient did not show any T or NK cells (Extended Data Fig. 10a, b ). From 3% to 11% of the treated cell progeny became GFP 1 , depending on primitive versus committed progenitor status ( Fig. 5c ). CFC assays yielded three GFP 1 colonies out of ,100 scored (Extended Data Fig. 10c ). Flow cytometry showed normal expression of the c-chain protein in the myeloid progeny of the GFP 1 CFCs (Fig. 5d ). Polymerase chain reaction (PCR) analyses of these colonies proved targeted integration into IL2RG leading to expression of the expected fusion transcript between the corrective cDNA and the upstream endogenous exons (Fig. 5e , f and Supplementary Information). Overall, these data show reconstitution of a functional IL2RG gene on targeted editing of a SCID-X1 allele in HSPCs.
Discussion
Here we developed a strategy for targeted genome editing in human long-term repopulating HSCs and exploited it to insert transgenes into a genomic safe harbour or downstream of the promoter of an endogenous gene to reconstitute its functional expression. Using the latter approach, we demonstrate correction of the defective IL2RG gene in HSPCs from a subject with SCID-X1. As we obtained consistent results when targeting two different loci, we expect that our genome editing strategy can be used to target a variety of genomic sites. As the procedure uses a combination of IDLV infection and mRNA electroporation to deliver donor template and ZFNs, it has the potential to be applicable to a range of other genome editing tools.
We found that primitive cells are more sensitive than committed progenitors to the cytotoxicity of the gene targeting procedure and less proficient at performing HDR, probably because of their quiescence or slow cycling. These findings are consistent with reports showing delayed DNA repair and enhanced apoptosis after c-radiation in human HSCs as compared to progenitors 30 and preferential repair of DNA DSBs by NHEJ in quiescent murine HSCs 31 . By delaying the time of treatment and exploiting compounds reported to support ex vivo maintenance and expansion of HSCs 26-28 , we were able to partially relieve the block to HDR. This effect is probably due to an increased transit through the S/G2 phases of the cell cycle, when HDR can occur, and, possibly, upregulation of its endogenous machinery. Other beneficial effects might be increased permissiveness to gene delivery, more efficient mRNA translation and reduced growth arrest and apoptosis in response to the gene targeting procedure. As improved procedures for ex vivo HSC expansion become available, they might increase the yield of gene targeted cells and allow their selection before in vivo administration. This would enable wide application of safe harbour sites, such as AAVS1, for robust expression of therapeutic transgenes 22, 23 .
When applied to the functional correction of IL2RG in HSCs, we show that our strategy is compatible with normal development of the lymphoid lineages. IL2RG-edited lymphoid cells repopulated the mice and responded to c-chain-dependent cytokines indistinguishably from 
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their unedited counterparts. On the contrary, lymphoid cells carrying NHEJ-mediated IL2RG inactivation were counter-selected in the mice, phenocopying the SCID-X1 disease 1 . This disease may be suitable for the clinical translation of targeted gene correction, as previous clinical studies have demonstrated the potential efficacy but also the risks of HSC gene therapy using early generation vectors 7, 8 . Whereas our strategy should abrogate the risk of insertional mutagenesis and the concern for unregulated transgene expression, it remains to be established whether a potentially limiting amount of targeted HSPCs would enable effective and safe correction of SCID-X1 in humans (even though both HSCs and progenitors, which are more efficiently targeted, would help repopulating the absent lymphoid lineages). Another concern is with the potential off-target activity of ZFNs, although our analysis showed a high specificity for the IL2RG ZFNs used in this study. Overall, we envisage a fairly straightforward path to clinical translation of our strategy, considering that good manufacturing practice of lentiviral vector and mRNA electroporation are already established. Moreover, infusion of autologous gene-targeted cells could be performed without pharmacological conditioning, taking advantage of the selective advantage of the corrected cells.
METHODS SUMMARY
Donor IDLV for HDR were generated as described. ZFNs targeting intron 1 of PPP1R12C or exon 5 of IL2RG (refs 16, 22) were expressed by mRNA electroporation. CD34 1 cells from human umbilical cord blood or bone marrow were used on approval by the San Raffaele Hospital Bioethical Committee, stimulated in serum-free medium with early acting cytokines, infected with IDLVs at a multiplicity of infection (MOI) 100-500, and then electroporated with 175 mg ml 21 ZFNs encoding mRNAs. Targeted integration was assessed by PCR and Southern blot while ZFN activity was determined by Cel1 assay and deep sequencing of genomic target sites. The treated CD34 1 cells at day 4 of culture were infused intravenously into sublethally irradiated 8-11-week-old NOD-SCID-Il2rg 2/2 (NSG) mice. To expand human T and NK cells, 4 3 10 6 MDA3-MB231 tumour cells expressing human IL-7, IL-15 and GM-CSF were implanted orthotopically in the mammary fat pad of NSG mice 14 weeks after CD34 1 cells transplantation 29 . Functional assays on IL2RG-edited T cells collected from transplanted mice were carried out after stimulation with beads conjugated to anti-human CD3 and CD28 antibodies and sorting for GFP expression.
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METHODS
Vectors and zinc finger nucleases. Homology-directed repair donor templates were generated from HIV-derived, third-generation self-inactivating transfer constructs. IDLV stocks were prepared as previously described 14 and titred by a qPCR designed to discriminate the reverse-transcribed vector genome from plasmid carried over from transient transfection 32 . Sequence and maps of AAVS1-PGK.GFP were previously reported 22 , whereas IL2RG-cDNA.PGK.GFP is described in detail elsewhere (Firrito et al., manuscript in preparation). ZFNs that target intron 1 of PPP1R12C or exon 5 of IL2RG were previously described 14, 16, 22, 33 . The latter pair was modified to contain high-fidelity obligate heterodimeric FokI variants 34 . Both pairs of ZFNs were transiently expressed as mRNAs. Plasmid templates for ZFNs mRNA production (described in Extended Data Fig. 1b ) were linearized and purified by phenol/chloroform extraction followed by ethanol DNA precipitation. 2 mg per reaction of linearized plasmid template was in vitro transcribed at 37 uC for 2 h using T7 RNA polymerase and 7.5 mM nucleotide triphosphates (MEGAscript kit; Ambion). Cap0 mRNAs were generated by supplementing the reactions with 6 mM m7(3'-O-methyl)-G(5')ppp(5')G, a non-reversible cap analogue (ARCA, New England Biolabs) and lowering the concentration of GTP to 1.5 mM. After TURBO DNase treatment (4 U per reaction, 1 h at 37 uC), mRNAs were poly(A) tailed with E. coli Poly(A) Polymerase (8 U per reaction) for 1 h at 37 uC (PolyA tailing kit; Ambion), yielding $150 nt polyA. Transcripts were purified by the RNeasy Plus Mini Kit (Qiagen). All RNA samples were analysed by denaturing agarose gel electrophoresis for quality assurance.
In vitro culture and assays on human cord blood or bone-marrow-derived CD34 1 cells. CD34 1 cells were either freshly purified from human cord blood after obtaining informed consent and on approval by the San Raffaele Hospital Bioethical Committee, or purchased frozen from Lonza. 10 6 CD34 1 cells per ml were stimulated in serum-free StemSpan medium (StemCell Technologies) supplemented with penicillin, streptomycin and human early-acting cytokines (for cord-blood-derived cells: stem cell factor (SCF) 100 ng ml 21 , Flt3 ligand (Flt3-L) 100 ng ml 21 , thrombopoietin (TPO) 20 ng ml 21 , and interleukin 6 (IL-6) 20 ng ml 21 ; for bone-marrow-derived cells: SCF 300 ng ml 21 , Flt3-L 300 ng ml 21 , TPO 100 ng ml 21 , and IL-6 60 ng ml 21 ; all purchased from Peprotech) for 24 or 48 h and then infected with IDLVs at a multiplicity of infection (MOI) 100-500. The following day the cells were electroporated with 175 mg ml 21 ZFNs encoding mRNAs (P3 Primary Cell 4D-Nucleofector X Kit, program EO-100; Lonza). For some experiments, the following drugs were supplemented to the culture media: 1 mM SR1 (provided by T. Boitano and M. Cooke, GNF) added at every medium change, and 10 mM dmPGE2 (Cayman) added at the beginning of the culture, 1 h before and just after electroporation. For CFC assays, 800 cells per plate were seeded one day after electroporation in methylcellulose-based medium (MethoCult H4434, StemCell Technologies). Two weeks after plating, colonies were counted and identified according to morphological criteria. Flow cytometry. For immunophenotypic analysis of CD34 1 cells and their progeny (performed on FACSCanto II; BD Pharmingen), we used the antibodies reported in Supplementary Information. Single-stained and FMO-stained cells were used as controls. For quantitative flow cytometry we used Flow-count Fluorospheres (Beckman Coulter) according to the manufacturers' instructions. Apoptosis analysis was performed on CD34 1 cells one day after electroporation using peripheral-blood-conjugated Annexin V (Biolegend) and Apoptosis Detection kit with 7-Aminoactinomycin D (7AAD, BD Pharmingen) according to the manufacturers' instructions. Percentages of live (7AAD 2 , AnnexinV 2 ), early apoptotic (7AAD 2 , AnnexinV 1 ), late apoptotic (7AAD 1 , AnnexinV 1 ) and necrotic (7AAD 1 , AnnexinV 2 ) cells are reported. Cell sorting was performed using MoFlo XDP Cell Sorter (Beckman Coulter). Molecular analyses. For molecular analyses, genomic DNA was isolated with DNeasy Blood & Tissue Kit or QIAamp DNA Micro Kit (QIAGEN). Extraction of genomic DNA from colonies in CFC assays was performed with Lysis Buffer as previously described 5 . NHEJ in AAVS1 locus or IL2RG gene was detected by the mismatch selective Cel1 assay as previously described 14 . Primers for PCR amplifications to detect targeted integration or for the Cel1 assay are indicated in Supplementary Information. PCR amplicons were resolved on agarose gel and visualized by ethydium bromide staining. For Southern blot analyses, genomic DNA was extracted with Blood & Cell Culture DNA Midi Kit (QIAGEN) and digested using restriction enzymes (BglI for AAVS1 locus and BspHI for IL2RG) and probes (see Supplementary Information) both located outside of the homology regions included in the vectors. Matched DNA amounts were separated on 1% agarose, transferred to a nylon membrane and probed with 32 P-radiolabelled sequences indicated in Supplementary Information. Membranes were exposed in a Storage Phosphor Screen. For qPCR analysis, 200 ng of genomic DNA were analysed using primers and probes complementary to a vector backbone sequence (Primer Binding Site), the GFP sequence and human TERT, the latter amplification used as normalizer, as previously described 14 . For gene expression analysis on the SCID-X1 gene corrected colony, mRNA was extracted using the RNeasy Micro Kit (QIAGEN) and cDNA was synthetized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). The resulting cDNA was amplified before qPCR by Taqman PreAmp Master Mix Kit (Applied Biosystems) according to the manufacturers' instructions. Gene expression was performed in triplicate with a TaqMan Gene Expression assay specific for the recoded exon 7 of the IL2RG gene (Applied Biosystems; see Supplementary Information) in a 7900HT real-time PCR thermal cycler. The relative expression level of the recoded IL2RG gene was calculated by the DDCt method and represented as fold change relative to the housekeeping gene control (HPRT), as previously described 22 .
Mice transplantation and analysis. For the in vivo studies, 8-to 11-week-old NOD-SCID-Il2rg 2/2 (NSG) mice were purchased by Jackson laboratory. The experimental protocol was approved by the Institutional Animal Care and Use Committee of the San Raffaele Scientific Institute. At day 4 of culture, 3 3 10 5 gene targeted cord-blood-derived CD34 1 cells (or 7.5 3 10 5 bone-marrowderived cells) were infused intravenously into the mice after sub-lethal irradiation (200 cGy). Sample size was determined by the total number of available treated cells. Mice were attributed to each experimental group randomly. MDA3 human mammary carcinoma cell line was obtained by stable transduction of MDA-MB 231 cells with lentiviral vectors expressing the human cytokines GM-CSF, IL-7 and IL-15 from the PGK promoter, as previously described 29 . 4 3 10 6 MDA3 cells were implanted orthotopically in the mammary fat pad of NSG mice 14 weeks after CD34 1 cell transplantation or in age-matched untransplanted NSG mice. Human CD45 1 engraftment was followed by serial collections of blood from the mouse tail and, at the end of the experiment (12-23 weeks after transplantation), bone marrow and spleen were harvested and analysed for lineage composition and GFP content (see Supplementary Information for gating strategy). T lymphocyte analyses. Human T cells were enriched from splenocytes harvested from the transplanted mice using magnetic beads conjugated to anti-human CD3 and CD28 antibodies (Dynabeads human T-activator CD3/CD28; Invitrogen), following the manufacturers' instructions, and grown in Iscove's Modified Dulbecco's Media (IMDM) (GIBCO-BRL) supplemented with penicillin, streptomycin, 10% FBS and 5 ng ml 21 each of IL-7 and IL-15 (PeproTech) 21 .
For TCR V-b repertoire analysis, mRNA was extracted from the expanded T cells using the RNeasy Mini Kit (QIAGEN) and cDNA was synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Multiplex PCRs optimized from a previous work 35 were carried out on cDNA using V-b primers specific for 4 or 5 different families and a single FAM-labelled C-b primer. PCR products were fractionated on 6% polyacrylamide gel, visualized on Molecular Dynamics Typhoon 9410 (Amersham Biosciences) and analysed using ImageQuant TL 7.0 (Amersham Biosciences). V-b complexity was determined by counting the number of distinct peaks and graded on a score of 0-8 (ref. 36 ). The overall TCR complexity score was determined by summing up all 23 individual TCR V-b family-specific scores.
To analyse phosphorylation of downstream effectors of the IL-2RG pathway, T cells were starved overnight at 37 uC in IMDM without cytokines and then stimulated with IL-2 (1,000 IU ml 21 , 100 IU ml 21 , 10 IU ml 21 ; purchased from Novartis) or IL-15 (10 ng ml 21 , 5 ng ml 21 , 1 ng ml 21 ) at 37 uC for increasing times. Cells were then fixed in PBS 2% paraformaldehyde (PFA) for 10 min at 37 uC, and after washing in PBS 0.1% BSA (3 times), they were permeabilized with ice-cold absolute methanol for 7 min on ice. After 60 min incubation of each time point of cytokine stimulation with different dilutions of Pacific blue succinimidyl ester (PBSE) (Life Technologies), cells were washed, pooled and stained for flow cytometry.
For proliferation assay, 10 5 T cells were labelled with Cell Proliferation Dye eFluor 670 (eBioscience) according to the manufacturer's instructions. Labelled T cells were co-cultured in IMDM supplemented with penicillin, streptomycin, 10% FBS and 5 ng ml 21 each of IL-7 and IL-15, with different dilutions of MDA-MB 231 cells previously irradiated at 10,000 rad or stimulated for 3 days with PHA (2 mg ml 21 ). After 7 days of culture, cells were analysed by flow cytometry. Division index was calculated according to FlowJo software rules.
For IFN-c release assay, T cells were stimulated at 37 uC for 6 h with PMA (50 ng ml 21 ) and ionomycin (1 mg ml 21 ) in presence of 2 ml per ml of culture of BD Golgi Plug (BD Pharmingen). Cells were then fixed and permeabilized using the BD Cytofix/Cytoperm Kit (BD Pharmingen) and stained for flow cytometry.
Elispot assay for IFN-c release was performed as previously described 21, 29 . When the number of measured spots was above the detection limit of the plate reader (Eli.Expert, A.EL.VIS.), it was arbitrarily set to 500. Deep sequencing of potential IL2RG ZFN off-target loci. Genomic DNA from ZFN-treated CD34 1 cells or their progeny harvested from transplanted mice was amplified using the REPLI-g Mini Kit (QIAGEN) and the top-ranking candidate off-target genomic loci from our previous study 16 UT, untreated cells. mRNA electroporation outperformed all approaches tested in terms of frequency of transfected cells and protein expression level. Note that although IDLV infects the majority of cells in these conditions its expression is constrained by the unintegrated nature 32 . Because mRNA transfection drives a robust but short-lived spike of expression, it appeared best suited for ZFN delivery, allowing proficient activity of the nucleases at the genomic target site while avoiding prolonged exposure. b, Top: schematic representation (not in scale) of a plasmid DNA template used for in vitro mRNA transcription with the T7 promoter, the Kozak sequence and the XbaI restriction enzyme used for the plasmid linearization depicted. The protein domains of a ZFN are shown within the open reading frame (ORF). NLS, nuclear localization signal; ZFP, zinc finger protein; FokI, FokI nuclease domain. Middle: representative denaturing gel electrophoresis of in vitro transcribed mRNAs encoding for the pair of ZFNs specific for AAVS1, before (2) and after enzymatic polyadenylation (pA). The ZFN mRNAs were produced either as two separated transcripts (ZFN-L and ZFN-R) or as a single construct coding for both ZFNs linked by a Tav.2A self-cleavage peptide sequence (ZFN-L.2A.ZFN-R; bottom left). Bottom right: cord blood CD34 1 cells were electroporated either with the two separate transcripts or with the single mRNA co-expressing both ZFNs. ZFN activity was measured on treated cells as percentage of NHEJ detected at the ZFN target site by Cel1 assay 10 days after electroporation. c, Dose-response for AAVS1 targeting ZFN mRNAs in CD34 1 cells. Cord blood CD34 1 cells were transduced with integrase-defective lentiviral vector (IDLV) 14 bearing homology to the AAVS1 locus and expressing GFP, and then electroporated with the indicated escalating doses of AAVS1 ZFN mRNAs. ZFN activity was scored by measuring the extent of NHEJ-mediated repair at their genomic target site, and HDR was scored by the frequency of GFP 1 cells obtained in liquid culture. Left: NHEJ measured by Cel1 assay at day 10 after electroporation for the indicated dose of mRNA. Means 6 s.e.m. (n 5 3). Right: percentages of GFP 1 cells by flow cytometry 3 days after treatment. The percentages of viable cells (indicated on top of the histogram) were calculated as percentages of 7AAD negative cells gated on singlets. A dose-dependent increase in the percentage of NHEJ and GFP 1 cells was observed for the first three mRNA doses, whereas the highest dose caused a significant reduction in the number of viable cells, and a reduction in the efficiency of gene targeting. Based on these data, we selected the dose of 175 mg ml 21 RNA to perform all further experiments. d, Choice of delivery platform for the HDR donor template. Cord blood CD34 1 cells were either transduced with the AAVS1 donor IDLV and electroporated with the cognate ZFNs mRNAs, or co-electroporated with AAVS1 donor plasmid DNA and ZFN mRNAs. Left: cell viability measured by flow cytometry 3 days after electroporation, comparing untreated cells (UT) and gene-targeted cells using IDLV or plasmid as donor templates. ****P , 0.0001 (one-way ANOVA with Bonferroni's multiple comparison post-test). Right: percentage of GFP 1 cells using either donor templates. Means 6 s.e.m. (UT, n 5 3; IDLV, n 5 18; plasmid, n 5 10). *P , 0.05 (unpaired t-test). IDLV infection outperformed plasmid DNA electroporation in terms of the frequency of GFP 1 cells and cell viability, consistent with our previous findings in other primary cell types 14, 22 . e, Schedule optimization for ZFNs and donor template delivery. After one day of pre-stimulation, cord blood CD34 1 cells were first transduced with the AAVS1 donor IDLV and then electroporated at the indicated hours postinfection with ZFN mRNAs (left) or, on the contrary, first electroporated with ZFN mRNAs and then transduced with IDLV (right). The time lines of the experiments are shown on top of the histograms. The percentages of GFP 1 cells measured by flow cytometry 3 days after treatment and NHEJ measured by Cel1 assay 10 days after treatment are shown on bottom left. Bottom right: the percentage of GFP 1 cells is expressed as fold to the percentage achieved in the same experiment with the best strategy on the left. The highest frequency of GFP 1 cells was obtained by combining IDLV-based donor template delivery 24 h before ZFN mRNA electroporation. Sequential exposure to the two delivery platforms avoids competition for cell entry and minimizes mutual interference, probably due to activation of innate responses to exogenous nucleic acids or the timing of peak ZFN expression relative to IDLV reverse transcription and nuclear import. Fig. 1 ). Flow cytometry analysis was performed 2 days later using the gating strategy shown in Fig. 3a . Bars represent the percentage of GFP 1 cells (plotted on left axis) while the line shows the level of transgene expression (plotted on the right axis as MFI, measured in arbitrary units). Means 6 s.e.m. (n 5 16 on 6 cord blood donors). c, CD34 1 cells treated for targeted integration were sorted by FACS one day after electroporation according to the gating strategy shown in Fig. 3a . The sorted populations were sampled at the indicated times and levels of NHEJ at the ZFN target site (AAVS1) were determined by Cel1 assay (n 5 3). d, Apoptosis analysis performed one day after electroporation on CD34 1 cells transduced with IDLV and electroporated with ZFN mRNAs. Percentages of live (7AAD 2 , AnnexinV 2 ), early apoptotic (7AAD 2 , AnnexinV 1 ), late apoptotic (7AAD 1 , AnnexinV 1 ) and necrotic (7AAD 1 , AnnexinV 2 ) cells. Means 6 s.e.m. (n 5 5 on 4 cord blood donors). e, Representative growth curves of CD34 1 cells cultured in the presence or not of SR1 and treated (TI) or not (UT) with the protocol described in Fig. 1b . Note that the TI and UT growth curves are reproduced from Extended Data Fig. 1c . Addition of SR1 to the culture did not change the proliferation rate of the cells. Because SR1 did not increase the total number of cells but the percentage of more primitive cells in culture (Fig. 3c) , the absolute number of primitive cells is larger in cultures containing SR1. Overall, the addition of SR1 and PGE2 to the in vitro culture did not significantly affect the in vivo differentiation of treated cells. Notably, the increased human engraftment achieved with the optimized culture conditions (as illustrated in Fig. 3g ) correlates with increased T-cell output. c, Multilineage GFP marking in individual NSG mice transplanted with CD34 1 cells treated with the indicated protocols for targeted integration. Percentages of GFP 1 cells were calculated within the CD45 1 Lin 1 populations (represented with different data-point shapes) in different organs (represented by different data-point colours). The analysis was performed on peripheral blood 14 weeks after transplantation and on spleen and bone marrow at the end of the experiments. Only mice displaying $0.1% GFP 1 cells are represented in the graph (n 5 2 independent experiments). Note that when using the improved protocols for targeted integration GFP 1 cells are found in multiple lineages in all mice. d, Analysis of the primitive human compartment in the bone marrow of transplanted mice from c. Top: gating strategy used to define progenitors (CD34 1 CD38 1 ), multilymphoid progenitors (MLPs; CD34 1 CD38 2 CD90l ow/2 CD45RA 1 ), multipotent progenitors (MPPs; CD34 1 CD38 2 CD90 2 CD45RA 2 ) and HSCs (CD34 1 CD38 2 CD90 1 CD45RA 2 ). Bottom: percentages of GFP 1 cells within the defined populations. Means 6 s.e.m. (48 h SR1, n 5 4; 48 h PGE2, n 5 3; 48 h PGE2 SR1, n 5 5). e, DNA from total bone marrow cells of transplanted mice was analysed by PCR to determine TI into IL2RG. Each column represents one mouse. The schematics show the different sets of primers used to detect on-target insertions mediated by HDR or NHEJ (the latter shown with the vector in sense or reverse orientation with respect to IL2RG). Whereas evidence of HDR-mediated insertion of the cassette was retrieved from all mice assayed, there was also indication of some NHEJmediated integration of the donor IDLV. Trapping of IDLV at sites of NHEJ has been previously reported 16 . We note that our strategy could be adjusted to also exploit this type of insertion to drive transgene expression 24 and potentially increase the overall efficiency of gene correction (see schematic in Fig. 4a ). In such case, one should target insertion within an intron of the gene so that the splice acceptor site of the corrective cDNA is next in line for processing with the splice donor site of the upstream endogenous exon and any intervening sequence can be spliced out from the chimaeric transcript leading to reconstitution of a functional open reading frame (provided that the insertion occurred in the same orientation as gene transcription). An additional benefit of targeting an intronic sequence would be to spare exons from disruption by NHEJ, although this is of minor concern when dealing with already defective alleles. f, 15-23 weeks after the primary transplant, human CD34 1 cells were purified from the bone marrow of 11 mice from c (mice were chosen among those best engrafted with GFP 1 cells in the different CD34 1 cell treatment groups) and transplanted (one mouse to one mouse) into 7-11-week-old NSG mice. Secondary recipient mice were monitored for engraftment of human 
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Extended Data Figure 6 | Generation of T cells with substantial Vb TCR diversity from the engrafted gene-targeted HSPCs. a, Analysis of TCR Vb repertoire performed on PBMCs from a healthy donor. The histogram shows the frequency distribution of the different complementarity-determining region 3 (CDR3) lengths identified within the indicated Vb families. As expected from a highly polyclonal TCR repertoire, all Vb families display a Gaussian distribution of the CDR3 lengths. b, Frequency distribution of the different CDR3 regions measured as in a for the GFP 1 (left) and GFP 2 (right) T cells harvested from the transplanted C1, C5 and A4 mice from Extended Data Fig. 5c . c, Complexity score 36 assigned to each Vb family for the samples shown in b. The sum of the scores for all the family is plotted in Fig. 4g . Note that all the samples analysed display similar TCR Vb repertoire distributions, constrained for some families and more polyclonal for others, as might be expected for human T cells developed in haematochimaeric mice 41 , and that no significant differences are observed between the GFP 1 and GFP 2 cells. This finding indicates that the rate of gene targeting achieved in the transplanted stem/ progenitor cells does not detectably limit the generation of a polyclonal and functional T-cell repertoire in vivo. Bottom: fold changes in the levels of pSTAT5, pSTAT3 and pAKT relative to the time 0 of stimulation with the indicated maximal doses of IL-15 and IL-2 (n 5 3). Phosphorylation of STAT3 was used as a specificity control. P 5 ns (two-way ANOVA). b, Table showing the fold changes in the levels of pSTAT5 which are graphically represented in Fig. 4k . Statistics in the first column indicate significant change during time. ****P , 0.0001, ***P , 0.001 (twoway ANOVA). c, Heat map representing fold changes in pAKT and pSTAT3 levels after the indicated time of exposure (min) to increasing amounts of IL-2 or IL-15. P 5 ns between GFP 1 and GFP 2 cells (two-way ANOVA). Bases . Bases Myeloid cells are stained for CD15 and CD33, B cells for CD19, T cells for CD3 and NK cells for CD16. Right: c-chain expression within the indicated cell populations gated from the plots shown on the left. As expected from the missense R289X mutation, the c-chain protein is expressed on the cell surface but it is not functional, as indicated by the absence of T and NK cells in the patient. In Fig. 5 we show normal expression of the c-chain protein in the myeloid cell progeny of three gene-corrected CFCs from the patient cells (gene correction was proven by evidence of targeted integration in the only IL2RG allele of this male individual in the clonal CFC progeny and by the expression of the fusion transcript bearing the corrective cDNA). These data indicate normal c-chain expression from the reconstituted allele in the edited patient cells. c, Bright-field and fluorescence microscopy images of the three GFP 1 myeloid colonies obtained after IL2RG gene correction of SCID-X1 cells.
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